文献速递真菌感染

卡泊芬净药代动力学建模以制定儿科患者延长给药方案

Pharmacokinetic modelling of caspofungin to develop an extended dosing regimen in paediatric patients.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

本研究基于已发表的3月龄至17岁儿童数据建立卡泊芬净群体药代动力学模型,采用蒙特卡洛模拟评估每周两次延长给药方案。模拟显示,200 mg/m2每周两次、最大总剂量200 mg的方案所达到的暴露与注册的每日给药方案及常用药代动力学/药效学靶值相匹配。

要点

  • 基于3月龄至17岁儿童数据建立卡泊芬净二室群体药代动力学模型。
  • 模拟显示200 mg/m2每周两次、最大200 mg总剂量可匹配每日给药暴露。
  • 该延长方案暴露与常用药代动力学/药效学靶值相符。

核心结论

  • 模拟显示200 mg/m2每周两次、最大总剂量200 mg的方案所达到的暴露与注册的每日给药方案及常用药代动力学/药效学靶值相匹配。

研究设计与样本

  • 基于已发表的3月龄至17岁儿童数据建立群体药代动力学模型,并使用最终模型进行蒙特卡洛模拟。

主要发现

  • 含线性消除和固定指数异速增长的二室模型被判定为最能充分描述所研究儿科人群。
  • 模拟显示200 mg/m2每周两次、最大总剂量200 mg的方案所达到的暴露与注册的每日给药方案及常用药代动力学/药效学靶值相匹配。

关键数值与推荐

  • 以平均每周AUC0-24 h/MIC以及既往已报告儿科试验中报告的AUC0-24 h用于指导 adequate 暴露。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Echinocandins are commonly used in treatment and prophylaxis of invasive fungal diseases. Intravenous daily dosing for prophylaxis in the outpatient setting can however become a hurdle for adequate compliance in the paediatric population. OBJECTIVES: Simulations were performed to assess extended twice-weekly dosing for antifungal prophylaxis using caspofungin. METHODS: A population pharmacokinetic model was developed based on previously published data from children aged 3 months to 17 years. Using the final model, Monte Carlo simulations were performed to assess the dose needed for adequate exposure in a twice-weekly setting. Mean weekly AUC0-24 h/MIC together with reported AUC0-24 h from previously reported paediatric trials were used to guide adequate exposure. RESULTS AND CONCLUSIONS: A two-compartment model with linear elimination and allometric scaling using fixed exponents was found most adequate to describe the given paediatric populations. Simulations showed that a 200 mg/m2 twice-weekly regimen with maximal 200 mg total dose should result in exposures matching registered daily dosing as well as commonly used pharmacokinetic/pharmacodynamic targets.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Gastine S, Hempel G, Neely MN, et al. Pharmacokinetic modelling of caspofungin to develop an extended dosing regimen in paediatric patients. J Antimicrob Chemother. 2022. PMID: 35696555. doi:10.1093/jac/dkac182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。